Clinical Trial Update: Study Comparing the Tolerability and Viral Reduction of the Combination of IFN a-2b XL + Ribavirin Versus Peg IFN a-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4 [Phase 2]

View source ↗

Summary

A Phase 2 study comparing tolerability and viral reduction between IFN alfa-2b XL + Ribavirin and Pegylated interferon alfa-2b + Ribavirin in chronic hepatitis …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Interferon alfa-2b XL (Interferon alfa-2b)
• Pegylated Interferon Alfa-2b (pegylated interferon alfa-2b)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: Chronic Hepatitis C | Phase 2 | Status: UNKNOWN